Central Nervous System Disease
0
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
1 programComprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous SystemN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Boston ScientificDeep brain stimulation
Allergy TherapeuticsComprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Clinical Trials (2)
Total enrollment: 2,401 patients across 2 trials
Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM
Start: Sep 2016Est. completion: Dec 20181 patients
N/ATerminated
NCT00794352Allergy TherapeuticsComprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Start: Oct 20082,400 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,401 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.